CG Oncology (CGON) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for CG Oncology (NASDAQ: CGON):

• 4/27/2026 – CG Oncology had its price target raised by Royal Bank Of Canada from $73.00 to $79.00. They now have an “outperform” rating on the stock.
• 4/25/2026 – CG Oncology was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – CG Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/17/2026 – CG Oncology had its price target raised by JPMorgan Chase & Co. from $65.00 to $91.00. They now have an “overweight” rating on the stock.
• 4/11/2026 – CG Oncology was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/7/2026 – CG Oncology had its price target raised by HC Wainwright from $80.00 to $100.00. They now have a “buy” rating on the stock.
• 3/28/2026 – CG Oncology was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In other news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction on Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the transaction, the director directly owned 15,600 shares in the company, valued at approximately $1,138,956. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.40% of the company’s stock.

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.